Quality of life and prognosis in heart failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)

被引:40
作者
Tate, Charles W., III [1 ]
Robertson, Alastair D. [1 ]
Zolty, Ronald [1 ]
Shakar, Simon F. [1 ]
Lindenfeld, Joann [1 ]
Wolfel, Eugene E. [1 ]
Bristow, Michael R. [1 ]
Lowes, Brian D. [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO USA
关键词
quality; beta-blockers; heart failure;
D O I
10.1016/j.cardfail.2007.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Quality of life (QOL) was a prespecified secondary end point in the Beta-Blocker Evaluation of Survival Trial. The Beta-Blocker Evaluation of Survival Trial used four QOL questionnaires to evaluate patient health status over time in response to treatment with placebo or bucindolol. The goal of the current study was to determine the relationship between the different questionnaires, assess the effect of treatment on health status, and evaluate the association between changes in health status and prognosis. Methods: The San Diego Heart Failure (SDHF), Minnesota Living with Heart Failure (MLHF), Patient Global Assessment (PGA), and Physician Global Assessment (PhyGA) questionnaires were measured at baseline through 48 months of follow-up. For SDHF and MLHF, changes from baseline were calculated. Spearman correlation was used to assess relationships, and Cox Proportional Hazards regression was used to predict time to all-cause mortality, and mortality or heart failure hospitalization, bivariately and multivariately. To determine whether beta-blocker treatment affected QOL, the Wilcoxon rank-sum test was used to compare treatment groups. Results: At 12 months, SDHF (r = +0.56, P = .0001), PGA (r = +0.36, P = .0001), and PhyGA (r = +0.37, P = .0001) correlated with MLHF. SDHF (P = .0001), MLHF (P = .0004), PGA (P = .0001), and PhyGA (P = .0001) were all strongly associated with all-cause mortality, with low values of each associated with a lower hazard. For the combined end point of all-cause mortality or heart failure hospitalization, change in QOL with each instrument had a P value of .0001. At 12 months, bucindolol-treated patients had improvement in both PhyGA and PGA compared with placebo; neither the SDHF nor the MLWF instrument distinguished between the two treatment groups unless a worst-rank assignment was used for patients who died. Conclusion: The four instruments correlate with each other and predict clinical end points, suggesting that each is a valid measure of health status. According to the PGA and the PhyGA, bucindolol improves QOL.
引用
收藏
页码:732 / 737
页数:6
相关论文
共 50 条
[21]   Beta-blocker treatment in heart failure. Role of heart rate reduction [J].
Lechat P. .
Basic Research in Cardiology, 1998, 93 (Suppl 1) :148-155
[22]   Beta-blocker treatment in heart failure. Role of heart rate reduction [J].
Lechat, P .
BASIC RESEARCH IN CARDIOLOGY, 1998, 93 :148-155
[23]   Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction [J].
Arnold, Suzanne V. ;
Silverman, Daniel N. ;
Gosch, Kensey ;
Nassif, Michael E. ;
Infeld, Margaret ;
Litwin, Sheldon ;
Meyer, Markus ;
Fendler, Timothy J. .
JACC-HEART FAILURE, 2023, 11 (08) :893-900
[24]   Aerobic exercise prescription in patients with chronic heart failure: a review in the beta-blocker era [J].
Carvalho, Vitor Oliveira .
JOURNAL OF CARDIOVASCULAR MEDICINE, 2012, 13 (09) :570-574
[25]   Influence of Global Region on Outcomes in Heart Failure Beta-Blocker Trials [J].
O'Connor, Christopher M. ;
Fiuzat, Mona ;
Swedberg, Karl ;
Caron, Michael ;
Koch, Bruce ;
Carson, Peter E. ;
Gattis-Stough, Wendy ;
Davis, Gordon W. ;
Bristow, Michael R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (09) :915-922
[26]   Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction [J].
Ibrahim, Nasrien E. ;
Gaggin, Hanna K. ;
Turchin, Alexander ;
Patel, Harshali K. ;
Song, Yang ;
Trebnick, April ;
Doros, Gheorghe ;
Maya, Juan F. ;
Cannon, Christopher P. ;
Januzzi, James L. .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (01) :3-11
[27]   Resting Heart Rate Does Not Reflect the Degree of Beta-Blockade in Subjects with Heart Failure on Chronic Beta-Blocker Therapy [J].
Mignatti, Andrea ;
Sims, Daniel B. ;
Colombo, Paolo C. ;
Garcia, Luis I. ;
Bijou, Rachel ;
Deng, Mario C. ;
Jorde, Ulrich P. .
CARDIOVASCULAR THERAPEUTICS, 2009, 27 (01) :42-48
[28]   Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank [J].
Lanfear, David E. ;
Luzum, Jasmine A. ;
She, Ruicong ;
Li, Jia ;
Sabbah, Hani N. ;
Zeld, Nicole ;
Liu, Bin ;
Peterson, Edward ;
Keoki Williams, L. .
CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2023, 16 (02) :E003835
[29]   Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction [J].
Bayoumi, Essraa ;
Lam, Phillip H. ;
Enders, Robert ;
Arundel, Cherinne ;
Sheriff, Helen M. ;
Brar, Vijaywant ;
Jurgens, Corrine Y. ;
Deedwania, Prakash ;
Faselis, Charles ;
Allman, Richard M. ;
Fonarow, Gregg C. ;
Ahmed, Ali .
AMERICAN JOURNAL OF MEDICINE, 2022, 135 (05) :607-614
[30]   Safety and tolerance of beta-blocker treatment in elderly patients with heart failure. BETANIC study [J].
Yebra-Yebra, Miguel ;
Recio, Jesus ;
Carlos Arevalo-Lorido, Jose ;
Cornide-Santos, Luis ;
Manuel Cerqueiro-Gonzalez, Jose ;
Manzano, Luis .
MEDICINA CLINICA, 2010, 134 (04) :141-145